Company intelligence / Profile preview
RetiPharma
Copenhagen, Hovedstaden, Denmarkretipharma.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
RetiPharma is a private Danish biotechnology company developing therapies for degenerative and neurodegenerative eye disorders. The company appears to be focused on neuroprotective peptide-based therapeutics delivered to the eye, with its lead program RP001 being developed for retinal detachment. RetiPharma has described a proprietary in vivo translational platform intended to improve translation from animal models to human disease. Publicly available sources indicate a small private company based in Copenhagen, founded in 2015, and backed by BioInnovation Institute funding. Its pipeline appears to remain at the preclinical stage.
- Therapeutic areas
- Ophthalmology
- Modalities
- PeptidesSmall moleculeCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioInnovation Institute
Beyond the preview
Go deeper on RetiPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RetiPharma.